Theravance Biopharma
TBPH
96 hedge funds and large institutions have $1.22B invested in Theravance Biopharma in 2018 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 39 increasing their positions, 22 reducing their positions, and 14 closing their positions.
77% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 22
21% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 14
3% more funds holding
Funds holding: 93 → 96 (+3)
0.04% more ownership
Funds ownership: 86.03% → 86.07% (+0.04%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
21% less capital invested
Capital invested by funds: $1.55B → $1.22B (-$328M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WIM
Woodford Investment Management
London,
United Kingdom
|
+$16.8M |
| 2 |
Morgan Stanley
New York
|
+$13.7M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.32M |
| 4 |
JP Morgan Chase
New York
|
+$3.44M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$2.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$23.9M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.8M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.81M |
| 4 |
Millennium Management
New York
|
-$4.3M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.79M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Two Sigma Investments
New York
| – | -$511K | -15,656 | Closed |
|
|
OAC
102
OMERS Administration Corp
Toronto,
Ontario, Canada
| – | -$327K | -10,000 | Closed |
|
103
Man Group
London,
United Kingdom
| – | -$292K | -8,942 | Closed |
|
|
TCM
104
Tekla Capital Management
Boston,
Massachusetts
| – | -$264K | -8,083 | Closed |
|
|
SAM
105
Sectoral Asset Management
Montreal,
Quebec, Canada
| – | -$260K | -7,945 | Closed |
|
|
GC
106
Guggenheim Capital
Chicago,
Illinois
| – | -$240K | -7,349 | Closed |
|
|
USAA
107
United Services Automobile Association
San Antonio,
Texas
| – | -$210K | -6,417 | Closed |
|
108
Daiwa Securities Group
Tokyo,
Japan
| – | -$10K | -299 | Closed |
|
TBPH Hedge Fund Activity: Q4 2018 in Review
96 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q4 2018, worth a combined $1.22B — down 21% from $1.55B a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new TBPH positions and 14 closed out — a net gain of 3 holders — while 39 added to existing stakes and 22 trimmed.
The largest buyer was Woodford Investment Management, adding an estimated $16.8M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $23.9M sold.
- 96 institutional investors held Theravance Biopharma (TBPH) as of Q4 2018, up from 93 in Q3 2018.
- Funds reported $1.22B of Theravance Biopharma stock for Q4 2018, down 21% quarter-over-quarter.
- 17 funds opened new Theravance Biopharma positions in Q4 2018 and 14 closed out, a net change of +3 holders.
- The largest Theravance Biopharma buyer in Q4 2018 was Woodford Investment Management, an estimated $16.8M added.
- The largest Theravance Biopharma seller in Q4 2018 was Consonance Capital Management, an estimated $23.9M sold.
Based on aggregated 13F filings for Q4 2018.